Pipeline and Strategy - Arcus Biosciences has an advanced pipeline targeting TIGIT, Adenosine, and PD-1 pathways[7] - Domvanalimab (anti-TIGIT mAb) is rapidly advancing in randomized combinations[7] - Zimberelimab (anti-PD-1 mAb) enables portfolio combination strategies with a clear path to commercialization[7] - Arcus is uniquely positioned with intra-portfolio combinations not available to other companies[7] Financial Position and Collaboration - Arcus Biosciences has over $825 million in cash[7] - The Gilead collaboration provides resources and expertise to exploit multiple intraportfolio opportunities[7] Clinical Development and Milestones - Preliminary randomized data from ongoing trials are expected in multiple settings and combinations[7] - Interim analysis of Domvanalimab and Zimberelimab in 1L NSCLC (ARC-7) is expected in the first half of 2021[24] - Preliminary Phase 1/1b data for AB680 in 1L PDAC (ARC-8) is expected in Q1 2021[24] Clinical Activity - In late-line mCRC, Etruma + mFOLFOX-6 showed a disease control rate (DCR) of 76%[57] - In patients with 3L+ mCRC, Etruma + mFOLFOX-6 showed a DCR of 64%[57]
Arcus Biosciences (RCUS) Investor Presentation - Slideshow